ALARAlarum Technologies Ltd.

Nasdaq alarum.io


$ 27.84 $ 0.01 (0.04 %)    

Tuesday, 25-Jun-2024 15:57:13 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 27.94
$ 27.52
$ 0.00 x 0
$ 0.00 x 0
$ 26.77 - $ 28.01
$ 2.07 - $ 40.94
232,591
na
1.67B
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alarum-technologies-q1-eps-023-misses-028-estimate-sales-838m-beat-738m-estimate

Alarum Technologies (NASDAQ:ALAR) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of...

 alarum-estimates-q1-2024-quarterly-revenue-of-more-than-83m-and-all-time-high-operating-cashflow-of-32m

Subsidiary NetNut's revenues surged approximately 140% in the first quarter of 2024 compared to the equivalent period in 20...

 alarum-technologies-q4-eps-003-misses-026-estimate-sales-711m-beat-700m-estimate

Alarum Technologies (NASDAQ:ALAR) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of...

 alarum-technologies-q4-2023-gaap-eps-003-misses-026-estimate-sales-7107m-beat-7000m-estimate

Alarum Technologies (NASDAQ:ALAR) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 alarum-technologies-ltd-preliminary-q4-2023-results-sees-fy23-revenue-265m-up-41-yoy--cash-and-cash-equivalents-balance-was-108m-as-of-december-31-2023

Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) ("Alarum" or the "Company"), a global provider of internet access...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION